Mucosal Melanoma: An Overview of Recent Therapies.

IF 2.8 4区 医学 Q2 PHARMACOLOGY & PHARMACY Current pharmaceutical design Pub Date : 2026-01-01 DOI:10.2174/0113816128340751241220045149
Zachary Griffin, Jane Mattei
{"title":"Mucosal Melanoma: An Overview of Recent Therapies.","authors":"Zachary Griffin, Jane Mattei","doi":"10.2174/0113816128340751241220045149","DOIUrl":null,"url":null,"abstract":"<p><p>Mucosal Melanoma (MM) is an aggressive disease that is distinct from cutaneous melanoma in risk factors, prognosis, and treatment. Surgical treatment is currently the treatment of choice for localized disease; however, the recurrence rate is common. For advanced or metastatic disease, immunotherapy with PD-1 inhibitors and anti-CTLA is generally first-line treatment, however the overall responses to immunotherapy in MM are often lower and less robust when compared to that observed in cutaneous melanoma. Adoptive-TIL therapy has shown great promise. Other advances, particularly through the exploration of novel and combination therapies, are a step forward and a hope to improve outcomes in patients with mucosal melanoma. In this review, we summarize current treatment options for MM, and we updated future clinical trials available for this population of patients.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":"267-275"},"PeriodicalIF":2.8000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128340751241220045149","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Mucosal Melanoma (MM) is an aggressive disease that is distinct from cutaneous melanoma in risk factors, prognosis, and treatment. Surgical treatment is currently the treatment of choice for localized disease; however, the recurrence rate is common. For advanced or metastatic disease, immunotherapy with PD-1 inhibitors and anti-CTLA is generally first-line treatment, however the overall responses to immunotherapy in MM are often lower and less robust when compared to that observed in cutaneous melanoma. Adoptive-TIL therapy has shown great promise. Other advances, particularly through the exploration of novel and combination therapies, are a step forward and a hope to improve outcomes in patients with mucosal melanoma. In this review, we summarize current treatment options for MM, and we updated future clinical trials available for this population of patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
粘膜黑色素瘤:近期治疗综述。
粘膜黑色素瘤(MM)是一种侵袭性疾病,在危险因素、预后和治疗方面不同于皮肤黑色素瘤。手术治疗是目前治疗局限性疾病的首选;然而,复发率是常见的。对于晚期或转移性疾病,PD-1抑制剂和抗ctla的免疫治疗通常是一线治疗,然而,与皮肤黑色素瘤相比,MM对免疫治疗的总体反应通常较低且不那么强劲。过继性til疗法已显示出巨大的前景。其他的进展,特别是通过探索新的和联合疗法是向前迈出的一步,并希望改善粘膜黑色素瘤患者的预后。在这篇综述中,我们总结了MM目前的治疗方案,并更新了未来可用于该患者群体的临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
302
审稿时长
2 months
期刊介绍: Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
期刊最新文献
The JN.1 Variant: Emergence and Global Spread. Alcohol in Drug Delivery Systems: Scientific Roles and Islamic Ethical Considerations in Muslim Contexts. Integrated Network Pharmacology and Molecular Modeling Reveal Therapeutic Potential of Silybum marianum Compounds against NAFLD. Molecular Insights into the MdtABC Efflux Pump Genes in Clinical Salmonella typhi Isolates from Typhoid Patients. Shengjiang Xiexin Decoction Mitigates Irinotecan-Triggered Delayed-Onset Diarrhea by Modulating Short-Chain Fatty Acids and the TLR4-MyD88-JNK/ NF-κB Pathway.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1